Hillrom Launches Two New Respiratory Health Innovations: Volara™ System for Oscillation and Lung Expansion Therapy, and Synclara™ Cough System

Rhea-AI Summary

Hillrom (NYSE: HRC) has launched two innovative respiratory therapy devices: the Volara™ System and the Synclara™ Cough System. The Volara System provides oscillation and lung expansion therapy, proven to reduce hospital stays and time on ventilators. Clinical studies show a 31% reduction in postoperative pulmonary complications (PPC) and a significant decrease in ICU and ventilator duration. The Synclara Cough System offers non-invasive therapy to clear airways for patients with compromised lung function. Both systems are now available in the United States.

Positive

• Volara System reduces hospital length of stay by 1.6 days and time on ventilator by 64.4 hours.
• Synclara Cough System offers individualized treatment to assist patients with vital secretion evacuation.
• New devices enhance patient outcomes by providing effective respiratory therapies at home and in hospitals.

Negative

• None.

CHICAGO, July 13, 2020 /PRNewswire/ -- Global medical technology leader Hillrom (NYSE: HRC) today announced the launch of two new respiratory therapy devices: the Volara™ System, which provides hospital-grade oscillation and lung expansion (OLE) therapy, and the Synclara™ Cough System.

"As part of our vision of Advancing Connected Care™, we want to make it easy for patients to leave the hospital with the technologies they need to get better faster," said John Groetelaars, president and CEO of Hillrom. "Our new Volara System is proven to reduce hospital length of stay and time on a ventilator by delivering effective OLE therapy¹, and the Synclara Cough System, which delivers mechanical insufflation and exsufflation, helps keep upper airways clear. We're delighted to introduce these practical, accessible innovations to patients and their caregivers."

The Volara™ System
The Volara System delivers trusted OLE therapy, combining Continuous Positive Expiratory Pressure (CPEP), Continuous High-Frequency Oscillation (CHFO) and a nebulizer in one por­table, lightweight device. Respiratory therapies delivered by the Volara System are suitable for a number of acute and chronic conditions, including post-operative pulmonary complications, that are treated both in acute care settings and at home.

OLE therapy has been proven to deliver clinical and economic outcomes in acute care settings¹. Recently published research in the Journal of American College of Surgeons involving a 419-patient, two-phase multicenter study¹ showed that pulmonary treatment with OLE therapy, along with standard respiratory therapy, reduced the rate of certain post-procedural complications in high-risk surgical patients who underwent thoracic, upper abdominal or aortic open surgical procedures.

The impact of OLE therapy on Postoperative Pulmonary Complications (PPC) is clinically proven¹, with an overall significant relative reduction in PPC by 31% and a significant relative reduction in PPC among intubated patients of 47%. The study also demonstrated a significant reduction in mean length of hospital stay to 1.6 days, a clinically relevant reduction in ICU stays to two days, and a significant reduction of 64.4 hours for time-on-ventilator.

The Volara System is versatile, enabling patients to continue receiving OLE treatments with the precise settings they used in the hospital, at home. Volara can be used with a mouthpiece, face mask, tracheostomy or in-line on a ventilator.

The Synclara Cough System
The Synclara Cough System is a non-invasive therapy that simulates a cough to remove secretions in patients with compromised peak cough flow. The Synclara Cough System uses mechanical insufflation-exsufflation technology to clear secretions from the upper airways, representing the most complete solution available to assist patients with vital secretion evacuation. Synclara has been designed with the programmability and sensing technology to deliver a more individualized treatment, the portability and ease-of-use to improve the patient experience, and specialized patient training, therapy optimization and support.

"For patients with compromised lung function, cough simulation can be a lifesaving therapy," said Mr. Groetelaars. "With Synclara, we've developed a cough system that senses how a patient is breathing and automatically adjusts the cough cycle to match the patient's breathing rhythm, making it possible for caregivers to tailor therapies for specific patient needs."

The Volara System and Synclara Cough System are available in the United States.

About Hillrom
Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through connected smart beds, patient lifts, patient assessment and monitoring technologies, caregiver collaboration tools, respiratory care devices, advanced operating room equipment and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.

1. Huynh TT, Liesching TN, Cereda M, Lei Y, Frazer MJ, Nahouraii MR, Diette GB, Efficacy of Oscillation and Lung Expansion in Reducing Postoperative Pulmonary Complication, Journal of the American College of Surgeons (2019)

CONTACT INFORMATION
Investor Relations
Contact:     Mary Kay Ladone, Senior Vice President,                      Corporate Development, Strategy and                      Investor Relations Phone:         312-819-9387 Email:          marykay.ladone@hillrom.com	Contact:    Lorna Williams, Executive                     Director, Investor Relations and                     Strategy Phone:        312-233-7799 Email:          lorna.williams@hillrom.com
Media
Contact:    Howard Karesh, Vice President, Corporate Communications Phone:       312-819-7268                       Email:        howard.karesh@hillrom.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hillrom-launches-two-new-respiratory-health-innovations-volara-system-for-oscillation-and-lung-expansion-therapy-and-synclara-cough-system-301091774.html

SOURCE Hillrom

FAQ

What is the Volara™ System launched by Hillrom?

The Volara™ System is a portable device that delivers oscillation and lung expansion therapy proven to reduce hospital stays and ventilator time for patients.

What are the benefits of the Synclara™ Cough System?

The Synclara™ Cough System simulates a cough to help clear secretions in patients with compromised lung function, improving their respiratory health.

When were the new respiratory therapy devices launched by Hillrom?

The new devices were launched on July 13, 2020.

What is the impact of OLE therapy from the Volara System on postoperative patients?

OLE therapy has shown a 31% reduction in postoperative pulmonary complications and a significant decrease in ICU stays for high-risk surgical patients.

Where are the Volara and Synclara systems available?

Both the Volara™ and Synclara™ systems are currently available in the United States.